Key facts
- Xinnate’s last known valuation is $38.8M (Dec 2022).
- It has raised $16.1M; the latest was Later Stage VC ($3.2M) in Jul 2025.
- Notable investors include United States Department of War, Jinderman & Partners, SmiLe Incubator, Swedish Research Council.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Xinnate
- ·The full record, as it builds
Funding rounds
No funding rounds for Xinnate are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xinnate
Developer of a biopharmaceutical platform intended to develop proprietary peptides for the prevention and treatment of wounds and topical applications. The company's platform develops products based on one of the natural defense mechanisms that have been shown to have a sustainable anti-inflammatory and antibacterial effect regardless of multi-resistance, enabling the pharmaceutical industry to get functionalized biomaterials and cost-efficient treatment in a growing market of wounds and surgery.
- Sector
- Healthcare
- HQ
- Lund, Sweden
- Founded
- 2019
- Employees
- 7
- Website
- xinnate.com/
- Ownership
- Privately Held (backing)
Xinnate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xinnate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xinnate in its N-PORT filings yet. We sweep new filings monthly.